ANI Pharmaceuticals announced the results of the NEW DAY clinical trial for ILUVIEN® (fluocinolone acetonide) in diabetic macular edema (DME) patients during the ASRS Annual Scientific Meeting. The ...

Data highlight ILUVIEN’s advantages as the only therapy that consistently treats diabetic macular edema (DME) for up to 3 years ATLANTA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc.

ATLANTA, Sept. 29, 2014 -- Alimera Sciences, Inc. (ALIM) ("Alimera"), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic ...

Alimera Sciences Limited, the European subsidiary of Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of ...

To report the 12-months visual and anatomical outcomes of chronic diabetic macular oedema (DMO) treated with ILUVIEN in a real-world clinical practice in a single tertiary referral centre.

ATLANTA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned ...

Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced ...

DALLAS. (KFSN) -- Diabeties is a leading cause of blindness in American adults. Partially because it is often missed until it is too late. Now, a new treatment is helping save patients' sight.

Marbury Creative Group and Alimera Sciences are aiming to get diabetic macular edema (DME) treatment Iluvien on patients’ radars with the See Less to See More campaign. The nine-month effort, which ...

Please provide your email address to receive an email when new articles are posted on . Alimera Sciences has initiated enrollment for its prospective Iluvien study New Day, according to a press ...

We report the clinical efficacy and safety of intravitreal Iluvien implant in vitrectomised eyes of chronic diabetic macular oedema (DMO), irrespective of the timing of vitrectomy procedure. Case 1 A ...